News | Radiopharmaceuticals and Tracers | April 05, 2017

GE Healthcare Signs Agreement With HealthTrust to Supply Radiopharmaceuticals

Member hospitals of Nashville-based organization will receive extended access to products that support the diagnosis and care of oncological, cardiological and neurological diseases

GE Healthcare, HealthTrust, supply agreement, nuclear imaging, radiopharmaceuticals

April 5, 2017 — GE Healthcare has signed an agreement with HealthTrust, a group purchasing organization headquartered in Nashville, Tenn., to provide both low-energy (SPECT) and high-energy (PET) radiopharmaceuticals to HealthTrust members across the United States. The agreement commenced on March 1, 2017.

GE Healthcare’s core imaging business manufactures pharmaceuticals that are used in the fields of radiology and nuclear medicine to assist physicians in diagnosing a range of diseases, including cancer and cardiovascular and neurological diseases. Through this agreement, HealthTrust member facilities will have access to Life Sciences Core Imaging single-photon emission computed tomography (SPECT) proprietary products, such as Myoview, Ceretec and Indium-Oxine, as well as non-GE Healthcare products, such as MDP, Indium In-111, Thallium chloride and Sodium Iodide 1-123 capsules.

HealthTrust serves approximately 1,600 acute care facilities and members in more than 26,000 other locations, including ambulatory surgery centers, physician practices, long-term care and alternate care sites.

For more information: www.gehealthcare.com

Related Content

This is 4MD’s cardiac nuclear imaging analysis software, shown here integrated with a ScImage cardiovascular information system (CVIS). Both companies displayed on the expo floor at ASNC 2019. The software creates a single page report seen here. PET perfusion imaging was a big topics at the conference. #ASNC #ASNC19 #ASNC2019

This is 4MD’s cardiac nuclear imaging analysis software, shown here integrated with a ScImage cardiovascular information system (CVIS). Both companies displayed on the expo floor at ASNC 2019. The software creates a single page report seen here. PET perfusion imaging was a big topic at the conference.

Feature | Nuclear Imaging | November 22, 2019 | Dave Fornell, Editor
There were a few key takeaways from the American Society of Nuclear Cardiology (ASNC) 2019 annual meeting in September...
Videos | Nuclear Imaging | November 07, 2019
American Society of Nuclear Cardiology (ASNC) President Rob Beanlands, M.D., shares a couple trends he sees in cardiac...
Videos | Nuclear Imaging | November 06, 2019
Doctor Robert Hendel explains some of the new cardiac radiotracers in the pipeline that were discussed in sessions at...
With the advent and optimization of nuclear scintigraphy protocols using bone-avid radiotracers, cardiac amyloidosis caused by transthyretin protein (ATTR) can now be diagnosed noninvasively without a costly tissue biopsy. The radiotracer 99mTc-pyrophosphate (99mTc-PYP) binds to deposited ATTR amyloid fibrils in the myocardium and can be visualized using planar and SPECT imaging. The image shows how SPECT allows the reader to distinguish between blood pool activity and radiotracer uptake.

With the advent and optimization of nuclear scintigraphy protocols using bone-avid radiotracers, cardiac amyloidosis caused by transthyretin protein (ATTR) can now be diagnosed noninvasively without a costly tissue biopsy. The radiotracer 99mTc-pyrophosphate (99mTc-PYP) binds to deposited ATTR amyloid fibrils in the myocardium and can be visualized using planar and SPECT imaging. This is Figure 2, showing how SPECT imaging allows the reader to distinguish between blood pool activity (ventricular cavity, etc) and myocardial activity and identify regional myocardial differences in radiotracer uptake.

Feature | Nuclear Imaging | July 22, 2019 | Christopher A. Hanson M.D., and Jamieson M. Bourque M.D., MHS
Cardiac amyloidosis is a highly morbid and underdiagnosed infiltrative cardiomyopathy that is characterized by the de
GE Healthcare Recalls Millennium Nuclear Medicine Systems
News | Nuclear Imaging | November 15, 2018
GE Healthcare announced it is recalling its Millennium Nuclear Medicine Systems due to an incident in which the the top...
Technology and Radionucleotide Development Will Fuel Mobile Gamma Camera Adoption
News | Nuclear Imaging | September 27, 2018
Advancements in healthcare technology, particularly in the surgery category, have led to an increasing adoption of...
Videos | Nuclear Imaging | August 21, 2018
Rami Doukky, M.D., professor of medicine, preventive medicine and radiology, and chief of the Division of Cardiology
ASNC Announces Keynote Speakers for 2018 Annual Scientific Session
News | Nuclear Imaging | August 08, 2018
August 8, 2018 — The American Society of Nuclear Cardiology’s (ASNC) Annual Scientific Session, ASNC2018, will kick o
Overlay Init